Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Faes FarmaXMAD:FAE -1.32%92 Debt-to-EBITDA is 2.11 as of Jun. 2026, which is 1011% above its 10-year median of 0.19. GuruFocus rates XMAD:FAE with a GF Score™ of 92/100 and a GF Value™ of €5.45 (Modestly Undervalued). The stock has 7 warning signs investors should review. Among 691 Drug Manufacturers companies, Faes Farma ranks worse than 65.41% on this metric.
Debt-to-EBITDA measures a company's ability to pay off its debt.
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
The historical rank and industry rank for Faes Farma's Debt-to-EBITDA or its related term are showing as below:
XMAD:FAE'
s Debt-to-EBITDA Range Over the Past 10 Years
Min: 0.03 Med: 0.19 Max: 3.54
Current: 2.8
During the past 13 years, the highest Debt-to-EBITDA Ratio of Faes Farma was 3.54. The lowest was 0.03. And the median was 0.19.
XMAD:FAE's Debt-to-EBITDA is ranked worse than 65.41% of 691
companies
in the Drug Manufacturers industry
Industry Median: 1.68
vs XMAD:FAE: 2.80
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.
According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
Faes Farma Debt-to-EBITDA Related Terms
Faes Farma Debt-to-EBITDA Historical Data
* Premium members only.
The historical data trend for Faes Farma's Debt-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
XMAD:FAE vs ZTS, UTHR, VTRS: Debt-to-EBITDA Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Faes Farma's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Faes Farma Debt-to-EBITDA vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Faes Farma's Debt-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Faes Farma's Debt-to-EBITDA falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data,
the EBITDA data used here is two times the quarterly (Jun. 2026) EBITDA data.
Faes Farma (XMAD:FAE) has a Debt-to-EBITDA of 2.11 as of Jun. 2026. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Faes Farma. This is 1011% above median its historical median of 0.19. Over the past decade, Faes Farma's Debt-to-EBITDA has ranged from 0.03 to 3.54. According to the industry distribution chart, Faes Farma ranks #452 out of 691 companies in the Drug Manufacturers industry, placing it in the top 65.4%.
Is Faes Farma's Debt-to-EBITDA too high?
Faes Farma's current Debt-to-EBITDA of 2.11 is 1011% above median its 10-year median of 0.19. Over the past 10 years, this metric has ranged from a low of 0.03 to a high of 3.54. The Drug Manufacturers industry median Debt-to-EBITDA is 1.68. Faes Farma's value of 2.11 is 25.6% above this industry median. Based on the distribution chart, Faes Farma ranks #452 out of 691 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Faes Farma has a GF Score™ of 92/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Faes Farma's Debt-to-EBITDA compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Faes Farma ranks #452 out of 691 companies for Debt-to-EBITDA. This places Faes Farma in the lower half of its industry. The industry median Debt-to-EBITDA is 1.68. Faes Farma's value of 2.11 is 25.6% above this benchmark. Historically, Faes Farma's own Debt-to-EBITDA has ranged from 0.03 to 3.54 over the past decade. While the company's 10-year median is 0.19 vs. the industry median of 1.68, Faes Farma has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-EBITDA for a Drug Manufacturers company?
The median Debt-to-EBITDA among Drug Manufacturers companies is 1.68, based on 691 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Faes Farma's current Debt-to-EBITDA of 2.11 is 25.6% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-EBITDA mean?
A high Debt-to-EBITDA can signal that a stock is expensive relative to its fundamentals. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Faes Farma. For the Drug Manufacturers industry, the median Debt-to-EBITDA is 1.68 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Faes Farma's current Debt-to-EBITDA is 2.11, which is 1011% above median its own 10-year median of 0.19. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Faes Farma stock overvalued right now?
Based on GuruFocus' analysis, Faes Farma (XMAD:FAE) is currently considered Modestly Undervalued. The stock's GF Value™ is €5.45, compared to a current price of €4.50 — trading 17.4% below its estimated fair value. The current Debt-to-EBITDA is 2.11, which is 1011% above median its 10-year median of 0.19 and 25.6% above the Drug Manufacturers industry median of 1.68. Faes Farma's overall GF Score™ is 92/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-EBITDA calculated?
Debt-to-EBITDA is calculated from a company's financial statements. For Faes Farma (XMAD:FAE), the current Debt-to-EBITDA is 2.11 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Faes Farma (XMAD:FAE) Overvalued in 2026?
Based on GuruFocus' analysis, Faes Farma stock appears to be undervalued.
The current stock price of €4.50 is trading 17.4% below its estimated GF Value™ of €5.45.
GuruFocus considers Faes Farma to be Modestly Undervalued.
Key valuation signals for XMAD:FAE:
Debt-to-EBITDA: 2.11 (1011% above median its 10-year median of 0.19)
GF Value™: €5.45 vs. price of €4.50 (17.4% below fair value)
Industry Position: 25.6% above the Drug Manufacturers median (#452 of 691)
No single metric tells the full story. See the XMAD:FAE stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Faes Farma SA purpose is manufacturing and selling all kinds of chemical and pharmaceutical products, foodstuffs, cosmetics, dietetics and medicinal plants, as well as acquiring, purchasing, disposing of, investing in, holding, using, managing, administering, marketing and leasing corporations, securities and real estate, patents, trademarks and registered brands and equity interests. It is mainly engaged in the manufacture and sale of pharmaceutical products, as well as in the manufacture and sale of animal nutrition and health products. Its segments are Pharmaceutical and healthcare specialities, Animal nutrition and health, and Other segments. It generates majority of revenue from Pharmaceutical and healthcare specialities. It operates mainly in domestic and international markets.
92GF Score
Get the complete analysis for XMAD:FAE
Debt-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XMAD:FAE has been successfully added to your 
